Multipathway Biomarker Profiling of Immunothrombosis in Moderate and Severe COVID-19
Journal of Clinical Medicine · 29.10.2026 · 15 (21) · 8444
DOI: 10.3390/jcm15218444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.10.2026. Verfasst von Giovanni Bousquet und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical Intensive Care Unit, North Hospital, Assistance Publique-Hôpitaux de Marseille (AP-HM), Chemin des Bourrely, 13015 Marseille, France. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Assistance Publique-Hôpitaux de Marseille.
Abstract (Originalsprache)
Background/Objectives: Coronavirus disease 2019 (COVID-19) is associated with immunothrombosis involving endothelial dysfunction and coagulation activation. We aimed to compare biomarkers spanning multiple immunothrombotic pathways between patients with moderate and severe COVID-19 at baseline and according to clinical outcome. Secondary analyses compared biomarker levels at days 3 and 7.
Methods
This prospective observational study included 42 hospitalized patients with COVID-19 enrolled between April 2020 and January 2021, comprising 21 with moderate and 21 with severe disease. Biomarkers of coagulation, endothelial dysfunction, endogenous anticoagulant pathways, fibrinolysis, and extracellular vesicle-mediated activity were measured at baseline and on days 3 and 7. The prespecified ventilation/death composite included invasive mechanical ventilation already ongoing at baseline or initiated subsequently and/or death by day 28.
Results
Seventeen patients (40.5%) met the composite criterion, including 12 patients already receiving invasive mechanical ventilation at baseline. At baseline, severe disease was associated with higher D-dimer (1.74 [0.87–3.67] vs. 0.68 [0.46–0.94] µg/mL FEU), free tissue factor pathway inhibitor (TFPI; 55.00 [38.00–109.00] vs. 16.00 [14.00–29.00] ng/mL), extracellular vesicle-associated tissue factor activity (EV-TF; 28.86 [13.61–48.72] vs. 5.00 [5.00–5.70] fM), and extracellular vesicle-associated plasmin generation capacity (EV-PGC; 93.36 [41.60–303.10] vs. 24.50 [16.14–35.74] fM; all p < 0.01). Exploratory ROC analyses further illustrated the separation of these biomarker distributions between the predefined clinical groups.
Conclusions
Severe COVID-19 and unfavorable outcomes were associated with baseline differences in biomarkers spanning several immunothrombotic pathways, some of which remained detectable at days 3 and 7. Interpretation of the marked TFPI elevation is limited by differences in heparin exposure between severity groups. These exploratory findings require confirmation in larger cohorts, and their incremental value beyond routine clinical assessment remains untested. Outcome analyses largely reflected baseline severity, with only five subsequent events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Intensive Care Unit, North Hospital, Assistance Publique-Hôpitaux de Marseille (AP-HM), Chemin des Bourrely, 13015 Marseille, France.
- Centre de Recherche en CardioVasculaire et Nutrition (C2VN), INSERM 1263, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (INRAE) 1260, Aix Marseille University, 13005 Marseille, Fra…
- Hematology Laboratory, La Timone University Hospital of Marseille, 13005 Marseille, France.
- Clinique des Bronches Allergies et Sommeil, CIC 9502, Hôpital Nord, AP-HM, Aix Marseille University, Chemin des Bourrely, 13015 Marseille, France.
- CNRS, EFS, ADES, Aix Marseille University, 13015 Marseille, France.
- Centre d'Etudes et de Recherches sur les Services de Santé et Qualité de vie EA 3279, 13005 Marseille, France.
ORCID-Profile: Giovanni Bousquet, Laurie Pahus, Karine Baumstarck, Damien Barrau, Christophe Guervilly
Förderung
- Assistance Publique-Hôpitaux de Marseille
Zitieren
APA
Bousquet, G., Lacroix, R., Pahus, L., Valera, S., Hezard, N., Arnaud, L., Abdili, E., Baumstarck, K., Barrau, D., Chanez, P., Dignat-George, F., Papazian, L., Forel, J. M., Hraiech, S., Morange, P., & Guervilly, C. (2026). Multipathway Biomarker Profiling of Immunothrombosis in Moderate and Severe COVID-19. Journal of Clinical Medicine, 15(21), 8444. https://doi.org/10.3390/jcm15218444
Vancouver
Bousquet G, Lacroix R, Pahus L, Valera S, Hezard N, Arnaud L, et al. Multipathway Biomarker Profiling of Immunothrombosis in Moderate and Severe COVID-19. Journal of Clinical Medicine. 2026;15(21):8444. doi:10.3390/jcm15218444
BibTeX
@article{Bousquet2026,
author = {Bousquet, Giovanni and Lacroix, Romaric and Pahus, Laurie and Valera, Sabine and Hezard, Nathalie and Arnaud, Laurent and Abdili, Evelyne and Baumstarck, Karine and Barrau, Damien and Chanez, Pascal and Dignat-George, Françoise and Papazian, Laurent and Forel, Jean-Marie and Hraiech, Sami and Morange, Pierre and Guervilly, Christophe},
title = {Multipathway Biomarker Profiling of Immunothrombosis in Moderate and Severe COVID-19},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8444},
doi = {10.3390/jcm15218444}
}
EUVIMED